Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio

Rhea-AI Summary

Microbot Medical (NASDAQ:MBOT) has secured its first patent in Japan for its LIBERTY® Endovascular Robotic System, strengthening its global intellectual property portfolio. The patent covers core technology including a compact robotic device for driving and manipulating elongate surgical tools.

The company has recently obtained patents in the U.S., China, and Israel over the past 90 days. Following FDA clearance on September 8, 2025, Microbot Medical is accelerating commercial launch plans, targeting an estimated 2.5 million annual peripheral endovascular procedures in the U.S. market.

Insights

Medical Device Patent Specialist

Microbot's LIBERTY robot secures Japanese patent protection alongside FDA clearance, strengthening commercial position in endovascular device market.

Microbot Medical has secured its first Japanese patent covering the core technology of its LIBERTY Endovascular Robotic System, a compact robotic device for manipulating elongate surgical tools. This comes as part of a broader intellectual property expansion, with additional patents granted in the US, China, and Israel within the past 90 days.

The timing is strategically significant, following the company's FDA clearance on September 8, 2025, which has allowed Microbot to accelerate its commercial launch. The LIBERTY system targets an estimated 2.5 million peripheral endovascular procedures performed annually in the US, representing a substantial market opportunity.

The Japanese patent is particularly valuable as Japan represents one of the largest medical device markets globally. The company's IP strategy appears well-executed, creating barriers to entry in major markets while potentially facilitating faster regulatory approvals in countries that recognize FDA clearance.

This coordinated approach of securing regulatory approval followed by patent protection in key markets suggests Microbot is executing a comprehensive commercialization strategy. For medical robotics, robust patent protection is crucial to prevent competitive copying while establishing market position in this high-margin sector. The combined FDA clearance and expanded patent portfolio significantly enhances Microbot's ability to protect its technology and establish market dominance in the endovascular robotics space.

Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices 

Protecting its Innovative Technology Remains a Priority and Momentum Increasing as Global Jurisdictions Acknowledge the Uniqueness of the LIBERTY System

HINGHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer, manufacturer and distributer of the innovative LIBERTY^® Endovascular Robotic System, today announced that the Japanese Patent Office has granted the Company its first patent in Japan, covering the core LIBERTY^® System technology, such as a compact robotic device for driving and manipulating movement of at least one elongate surgical tool. In addition to today’s news, the Company has also received patents in the U.S., China and Israel over the past 90 days.

The Company announced marketing clearance for the LIBERTY^® System by the U.S. Food and Drug Administration (FDA) on September 8, 2025, and has accelerated its commercial launch plans as it targets an estimated 2.5 million peripheral endovascular procedures performed in the U.S., annually. As the Company evaluates other future global markets that have historically accepted FDA cleared devices, the successful implementation of its global IP strategy is expected to protect and allow it to monetize its innovative technology.

“Our initial focus is on the US market, however, certain markets such as Japan, represent attractive and strategically important markets for the LIBERTY^® System,” commented Harel Gadot, Chairman, CEO & President. “Building on our recent FDA clearance of LIBERTY^®, we are evaluating opportunities to expand into other global markets that have traditionally taken FDA clearance into consideration to potentially expedite local approval and adoption.”

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a breakthrough medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

FAQ

What patent did Microbot Medical (MBOT) receive in Japan?

Microbot Medical received its first Japanese patent covering the core LIBERTY® System technology, specifically for a compact robotic device that drives and manipulates elongate surgical tools.

When did Microbot Medical receive FDA clearance for the LIBERTY System?

Microbot Medical received FDA clearance for the LIBERTY® Endovascular Robotic System on September 8, 2025.

How many peripheral endovascular procedures are performed annually in the US that MBOT is targeting?

Microbot Medical is targeting an estimated 2.5 million peripheral endovascular procedures performed annually in the U.S. market.

Which countries has Microbot Medical received patents in recently?

In the past 90 days, Microbot Medical has received patents in the United States, China, Israel, and Japan.

What is Microbot Medical's global market strategy for the LIBERTY System?

While focusing primarily on the U.S. market, Microbot Medical is evaluating expansion into global markets that traditionally accept FDA-cleared devices, with Japan identified as an attractive and strategic market.